Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare Source: Eur Respir J 2002; 20: Suppl. 38, 561s Year: 2002
Impact of age and gender on efficacy and safety of omadacycline (OMC) vs. moxifloxacin (MOX) in community-acquired bacterial pneumonia (CABP) Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018
The analysis of efficiency of amoxycillin/clavulanate (AC) usage at inpatients with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 2s Year: 2006
The efficiency of moxifloxacin (MOX) in community-acquired pneumonias (CAP) treatment while the initial antibacterial therapy (IAT) was inefficient Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005
Antibacterial activity of telithromycin (TEL) and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 186s Year: 2004
Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in PROTEKT years 1–5 (1999–2004) Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006
Impact of telithromycin (T), azithromycin (A) and cefuroxime axetil (C) on the carriage of resistant streptococcus pneumoniae (Sp ) in pts with acute exacerbation of chronic bronchitis (AECB) Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007
Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Change in the susceptibility pattern of Streptococcus pneumoniae (SP) and risk factors (RF) for antibiotic resistance (AR) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 546s Year: 2003
The impact of antimicrobial resistance on the cost-effectiveness of empirical treatment of community-acquired pneumonia (CAP) in France (FR), Belgium (BE) and Germany (DE) Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication Year: 2007
IV azithromycin (AZM)/ceftriaxone (CEF) followed by PO AZM vs IV levofloxacin (LEV) followed by PO LEV in treatment of hospitalized patients with community acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003
Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP) Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008
Efficacy of sequential intravenous (i.v. ) to oral (p.o. ) moxifloxacin in hospitalized patients with community-acquired pneumonia (CAP) due to m. pneumoniae or chlamydia spp. Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005
Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment Source: Annual Congress 2009 - Pulmonary infections Year: 2009
Determinants of performance of indicators on antibiotic use in community-acquired pneumonia (CAP) at hospitals Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005
Use of respiratory fluoroquinolones gatifloxacin for treatment of severe community-acquired pneumonia (SCAP) Source: Eur Respir J 2006; 28: Suppl. 50, 166s Year: 2006
Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015
Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005